BR112021018219A2 - Método de tratamento de endocardite infecciosa - Google Patents

Método de tratamento de endocardite infecciosa

Info

Publication number
BR112021018219A2
BR112021018219A2 BR112021018219A BR112021018219A BR112021018219A2 BR 112021018219 A2 BR112021018219 A2 BR 112021018219A2 BR 112021018219 A BR112021018219 A BR 112021018219A BR 112021018219 A BR112021018219 A BR 112021018219A BR 112021018219 A2 BR112021018219 A2 BR 112021018219A2
Authority
BR
Brazil
Prior art keywords
infective endocarditis
sublevel
mic
antibiotics
plyss2 lysine
Prior art date
Application number
BR112021018219A
Other languages
English (en)
Inventor
Raymond Schuch
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of BR112021018219A2 publication Critical patent/BR112021018219A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

método de tratamento de endocardite infecciosa. a presente divulgação é direcionada a um método de tratamento ou prevenção de endocardite infecciosa devida a bactérias gram-positivas, como o s. aureus, método este que inclui a administração de uma quantidade terapeuticamente eficaz de uma combinação de um ou mais antibióticos, opcionalmente em um subnível de concentração inibitória mínima (mic), e uma lisina plyss2, tal como uma dose única de lisina plyss2 em um subnível de mic, em que os um ou mais antibióticos e a lisina plyss2 são administrados simultânea ou sequencialmente a um paciente que necessita destes em qualquer ordem.
BR112021018219A 2019-03-22 2020-03-20 Método de tratamento de endocardite infecciosa BR112021018219A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962822386P 2019-03-22 2019-03-22
US201962832708P 2019-04-11 2019-04-11
US201962849093P 2019-05-16 2019-05-16
US201962898379P 2019-09-10 2019-09-10
US202062965720P 2020-01-24 2020-01-24
PCT/US2020/024051 WO2020198073A1 (en) 2019-03-22 2020-03-20 Method of treating infective endocarditis

Publications (1)

Publication Number Publication Date
BR112021018219A2 true BR112021018219A2 (pt) 2022-01-18

Family

ID=72611751

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018219A BR112021018219A2 (pt) 2019-03-22 2020-03-20 Método de tratamento de endocardite infecciosa

Country Status (11)

Country Link
US (1) US20220160842A1 (pt)
EP (1) EP3941504A4 (pt)
JP (1) JP2022525914A (pt)
KR (1) KR20210141667A (pt)
CN (1) CN114025782A (pt)
AU (1) AU2020244764A1 (pt)
BR (1) BR112021018219A2 (pt)
CA (1) CA3134154A1 (pt)
IL (1) IL286389A (pt)
MX (1) MX2021011469A (pt)
WO (1) WO2020198073A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023023560A1 (en) * 2021-08-17 2023-02-23 Contrafect Corporation New uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012245391A1 (en) * 2011-04-21 2013-11-21 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
EP3252155A1 (en) * 2011-04-21 2017-12-06 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
ES2729123T3 (es) * 2012-05-09 2019-10-30 Contrafect Corp Rotura de biopelícula con lisina plyss2
IL308477A (en) * 2012-05-09 2024-01-01 Contrafect Corp Combinations of bacteriophage lysine and antibiotics against gram-positive bacteria
WO2017049233A2 (en) * 2015-09-17 2017-03-23 Contrafect Corporation Lysin polypeptides active against gram-negative bacteria
KR20190004799A (ko) * 2016-05-12 2019-01-14 콘트라펙트 코포레이션 항균 폴리펩티드의 최소 억제 농도를 평가 및 탐지하기 위한 배지미량희석법
JP2020527551A (ja) * 2017-07-10 2020-09-10 コントラフェクト コーポレイション 血液成分による溶菌タンパク質の抗菌活性の強化、並びにその方法及び使用

Also Published As

Publication number Publication date
IL286389A (en) 2021-10-31
KR20210141667A (ko) 2021-11-23
AU2020244764A1 (en) 2021-10-14
JP2022525914A (ja) 2022-05-20
WO2020198073A1 (en) 2020-10-01
CA3134154A1 (en) 2020-10-01
US20220160842A1 (en) 2022-05-26
EP3941504A4 (en) 2022-12-07
MX2021011469A (es) 2021-10-22
CN114025782A (zh) 2022-02-08
EP3941504A1 (en) 2022-01-26

Similar Documents

Publication Publication Date Title
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
EA201992722A1 (ru) N2,n4-дифенилпиримидин-2,4-диаминовое производное, способ его получения и фармацевтическая композиция, содержащая его в качестве активного ингредиента, для профилактики и лечения рака
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
BR112016030541A2 (pt) métodos para o tratamento de infecções fúngicas
WO2016090024A3 (en) Combination therapy for treatment of cancer
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
PH12021550713A1 (en) Medicament for the treatment of chronic cough
BR112013007423A2 (pt) terapia combinada no que diz respeito ao tratamento da infecção por hcv
BR112019001948A2 (pt) método de tratamento de um indivíduo humano.
WO2020076760A3 (en) Sphingoid compounds for use in the prophylaxis and/or therapy of a viral infection
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
EA202190171A1 (ru) Применение грамотрицательных видов для лечения атопического дерматита
BR112021018219A2 (pt) Método de tratamento de endocardite infecciosa
MX2017010837A (es) Dosis y metodos para administrar telavancina.
MY170991A (en) Dosing regimens of celgosivir for the treatment of dengue
PH12018501769A1 (en) Medicament for treatment of diabetic foot infections
MY193963A (en) Composition for treating joint diseases and kit containing same
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
EA201590350A1 (ru) Комбинации с пептидом с циклизованной основной цепью
MX2022011171A (es) Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos.
FI3038616T3 (fi) Menetelmiä bakteremian ja osteomyeliitin hoitamiseksi oritavansiinia käyttämällä